Catalog Number 04625374160 |
Device Problem
Incorrect, Inadequate or Imprecise Result or Readings (1535)
|
Patient Problems
Gastrointestinal Hemorrhage (4476); Melena (4480)
|
Event Date 06/17/2021 |
Event Type
Injury
|
Manufacturer Narrative
|
The meter and strips have been requested for return.The product has not been received at this time.If the product is returned in the future, a follow-up report will be submitted.Routine retention testing was performed.Test strip retention samples passed the internal inspection.Per product labeling, "coaguchek uses human recombinant thromboplastin.Therefore, the comparability to other human recombinant thromboplastins is best, whereas higher deviations can occur with other thromboplastins.However, those higher differences between thromboplastins of different (rabbit, bovine based) origin are not a coaguchek specific issue.Similar differences can be observed when a human recombinant thromboplastin-based laboratory method is compared against several other (rabbit, bovine-based) laboratory methods." the medical assessment stated the identified dieulafoy lesion is a large tortuous arteriole most commonly in the submucosal stomach wall, which erodes and bleeds.The presence of anticoagulation makes the risk for bleedings higher.An ulcus dieulafoy is not caused by anticoagulation, but is an independent medical condition.The patient's wife was aware of tarry stools 2 days prior to reporting it to the doctor on (b)(6) 2021.The patient's wife did not mention the tarry stools to the doctor at the time of the 2.3 inr on (b)(6) 2021 and the patient's warfarin dosage was increased by the doctor's advice based on this result which was slightly below therapeutic range of 2.5 - 3.5 inr.Different inr results on different days are generally not comparable.Initial reporter occupation was lay user/patient.
|
|
Event Description
|
There was an allegation the patient was hospitalized for bleeding of the stomach lining while using coaguchek xs meter serial number (b)(4).On (b)(6) 2021 at an unknown time, the result was 2.3 inr.Based on the meter result and the doctor's advice, 1.5 mg of warfarin was added to the normal 3 mg dose for that day.The patient's wife had noticed a darkening of the stool two days before reporting it to the doctor on (b)(6) 2021.The patient had not mentioned the darker stools to the doctor on the (b)(6) 2021 prior to the warfarin adjustment.On (b)(6) 2021, the patient also had symptoms of weakness and issues standing.The patient was taken to the hospital er and then sent to another hospital where blood work was performed.The warfarin was stopped for three days based on a laboratory result of 4.8 inr.The laboratory reagent was not known.On (b)(6) 2021, an endoscopy determined the bleeding was caused by a rare condition called dieulafoy lesions (defined as a vascular abnormality, most commonly in the stomach wall, that erodes and bleeds).During the endoscopy, the bleeding section of the stomach lining was cauterized and clipped.The patient received one unit of blood in the er and two units of blood later in the hospital.The patient's inr results were reported to be "still high" on release from the hospital.The patient's inr result was estimated to be above 4.0 inr but less than 4.8 inr.The patient was advised to withhold warfarin from (b)(6) 2021.The patient began taking 1 mg warfarin on (b)(6) 2021.The therapeutic range was 2.5-3.0 inr and the patient tests weekly.
|
|
Search Alerts/Recalls
|
|